CTOs on the Move

Carbon Sciences, Inc

www.carbonsciences.com

 
Carbon Sciences Inc. is developing a breakthrough technology to transform carbon dioxide (CO2) emissions into the basic fuel building blocks required to produce gasoline, diesel fuel, jet fuel and other portable fuels.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million
  • www.carbonsciences.com
  • 50 Castilian Drive Ste Suite C Ste Suite C
    Santa Barbara, CA USA 93117
  • Phone: 805.690.9090

Executives

Name Title Contact Details

Similar Companies

Ciitizen

Ciitizen is a platform that helps you collect, organize, and share your medical records digitally. Use it to get a second opinion, coordinate with a caregiver, and donate to research.

maryville academy

maryville academy is a Des Plaines, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Synlogic

Synlogic is a clinical-stage biotechnology company developing medicines through its proprietary approach to synthetic biology. Synlogic`s pipeline includes its lead program in phenylketonuria (PKU), which has demonstrated proof of concept with plans to start a pivotal, Phase 3 study in the second half of 2022, and additional novel drug candidates designed to treat homocystinuria (HCU) and enteric hyperoxaluria. The rapid advancement of these potential biotherapeutics, called Synthetic Biotics, has been enabled by Synlogic`s proprietary, reproducible, target-specific drug design. Synlogic uses programmable, precision genetic engineering of well-characterized probiotics to exert localized activity for therapeutic benefit, with a focus on metabolic and immunologic diseases. Synlogic is also working with Roche in a research collaboration focused on the discovery of a novel Synthetic Biotic for the treatment of inflammatory bowel disease and with Ginkgo Bioworks to include additional undisclosed preclinical assets, combining Synlogic`s approach to Synthetic Biotics with Ginkgo`s Codebase and Foundry services.

Biochrom

Biochrom is a Holliston, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Rani Therapeutics

Rani Therapeutics has developed the RaniPill™, a platform technology for the oral delivery of biologic drugs. Millions of patients with chronic conditions require biologic drugs that today can only be injected. These injections are painful and inconvenient and often affect both patient compliance and quality of life. The pharma industry has been searching for decades to convert injectables into pills, and we believe the solution is the RaniPill™ capsule. We have demonstrated bioavailability similar to subcutaneous injections in both preclinical and clinical studies. Rani has an internal pipeline of molecules, and active collaborations with Novartis and Takeda. The research and technology behind Rani Therapeutics came out of InCube Labs, a multi-disciplinary life sciences R&D lab focused on breakthrough medical innovations. InCube is led by Mir Imran, a prolific medical inventor, entrepreneur, and investor.